<DOC>
	<DOCNO>NCT02079883</DOCNO>
	<brief_summary>This multicenter , prospective , observational , Phase 4 study assess clinical outcome safety JETREA® administer real-world setting treatment symptomatic vitreomacular adhesion ( VMA ) assess anatomical functional outcome 1500 patient recruit across approximately 120 USA retina site .</brief_summary>
	<brief_title>Ocriplasmin Research Better Inform Treatment ( ORBIT )</brief_title>
	<detailed_description>The site prospectively enroll consecutive patient eligible participation study . Informed consent obtain prior data collect . This study observational ; therefore , treatment decision assessment discretion patient 's treating physician mandate study design protocol . Patients enrol routinely schedule visit , day JETREA® administration JETREA® injection . No specific visit , examination , laboratory test procedure mandate part study . There pre-set visit schedule , frequency time actual patient visit discretion treat physician follow standard care . All available relevant data collect prospectively .</detailed_description>
	<criteria>Adults 18 year old diagnose symptomatic VMA treat JETREA ® physician 's discretion manner consistent product label . Willing able provide write informed consent Patients treat JETREA® medical condition outside US product label . Concurrent participation research study prescribe ocular treatment , image and/or intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>